Notch activation promotes bone metastasis via SPARC inhibition in adenoid cystic carcinoma
Oral Diseases · 2024
DOI: 10.1111/odi.14573 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2024. Verfasst von Ye Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Pathology, Peking University School and Hospital of Stomatology, Beijing, China. Hauptthemen laut MEDLINE: Bone Neoplasms, Carcinoma, Adenoid Cystic, Osteonectin, Signal Transduction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: CAMS Innovation Fund for Medical Sciences, National Natural Science Foundation of China, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Objectives
We aimed to investigate bone metastasis induced by Notch signalling pathway dysregulation and to demonstrate that SPARC is a potential therapeutic target in adenoid cystic carcinoma (AdCC) with Notch dysregulation. Materials and Methods This retrospective study enrolled 144 AdCC patients. RNA‐sequencing and enrichment analyses were performed using 32 AdCC samples. Osteonectin/SPARC and the Notch activation indicator Notch intracellular domain (NICD) were detected using immunohistochemistry. Cell proliferation and migration assays were conducted using stably NICD over‐expressing cells. The effect of SPARC on osteoclast differentiation in NICD cells was investigated using western blotting, quantitative reverse transcription PCR, tartrate‐resistant acid phosphatase staining and resorption assays.
Results
RNA‐sequencing analysis showed that genes down‐regulated in Notch‐mutant AdCCs, such as SPARC , were enriched in ossification and osteoblast differentiation. Most (75/110, 68.2%) Notch1‐wild‐type AdCCs showed SPARC over‐expression, whereas 30 out of 34 (88.2%) Notch1‐mutant tumours showed low SPARC expression. SPARC over‐expression was then found negatively to be correlated with NICD expression in 144 AdCCs. NICD over‐expression promoted cell growth, migration and osteoclast differentiation, which could be partly reversed by exogenous SPARC.
Conclusions
Notch activation in AdCC contributes to bone metastasis through SPARC inhibition. The study results suggest that SPARC may represent a prognostic biomarker and potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Pathology, Peking University School and Hospital of Stomatology, Beijing, China.
- National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Research Center of Oral Biomaterials and Digital Medical Devices, Beijing, China.
- Research Unit of Precision Pathologic Diagnosis in Tumors of the Oral and Maxillofacial Regions, Chinese Academy of Medical Sciences (2019RU034), Beijing, China.
ORCID-Profile: Tie-Jun Li
Förderung
- CAMS Innovation Fund for Medical Sciences
- National Natural Science Foundation of China
- Natural Science Foundation of Beijing Municipality
Zitieren
APA
Zhang, Y., Liu, X., Zhu, L., Zhou, Z., Cui, Y., Zhou, C. X., & Li, T. J. (2024). Notch activation promotes bone metastasis via SPARC inhibition in adenoid cystic carcinoma. Oral Diseases. https://doi.org/10.1111/odi.14573
Vancouver
Zhang Y, Liu X, Zhu L, Zhou Z, Cui Y, Zhou CX, et al. Notch activation promotes bone metastasis via SPARC inhibition in adenoid cystic carcinoma. Oral Diseases. 2024. doi:10.1111/odi.14573
BibTeX
@article{Zhang2024,
author = {Zhang, Ye and Liu, Xiaoxiao and Zhu, Lijing and Zhou, Zheng and Cui, Yajuan and Zhou, Chuan-Xiang and Li, Tie-Jun},
title = {Notch activation promotes bone metastasis via SPARC inhibition in adenoid cystic carcinoma},
journal = {Oral Diseases},
year = {2024},
doi = {10.1111/odi.14573}
}
EUVIMED